Johannes Fermér
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johannes Fermér has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Anders Valind
Childhood Cancer Center Skåne University Hospital Lund Sweden
3 shared publications Arja Harila
Department of Women's and Children's Health Uppsala University Uppsala Sweden
3 shared publicationsHartmut Vogt
Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden
3 shared publicationsIsabella Donnér
Department of Pediatrics Institute of Clinical Sciences Sahlgrenska Academy University of Gothenburg Gothenburg Sweden
3 shared publicationsJonas Abrahamsson
Department of Pediatrics Institute of Clinical Sciences Sahlgrenska Academy University of Gothenburg Gothenburg Sweden
3 shared publications- Susanna Ranta
Unit for Pediatric Oncology Department of Women's and Children's Health Karolinska Institutet Stockholm Sweden
3 shared publications
Latest Publications
- Open Access
- 20 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (2) , e32168
Early Toxicity in Childhood Acute Lymphoblastic Leukemia: A Comparison of NOPHO ALL2008 and ALLTogether Protocols in Sweden
Background: The European ALLTogether protocol for childhood acute lymphoblastic leukemia, initiated in Sweden 2019, introduced earlier asparaginase during induction, dexamethasone instead of prednisone for all patients, and omitted anthracyclines from low‐risk induction to reduce treatment‐related toxicity. Consolidation‐1 was based on the Induction 1B‐phase developed by the BFM‐group, replacing mercaptopurine, methotrexate, and asparaginase used in the previous NOPHO ALL2008 protocol, ALL2008. Following implementation, early treatment toxicity was considered unacceptably high, prompting a protocol amendment. We compared the prevalence of 14 predefined toxicities, the number of inpatient days, and weight changes during induction and consolidation‐1 between the two protocols. Methods: We conducted a population‐based cohort study in Sweden, reviewing patient records from 117 children treated under ALLTogether protocol and 234 matched controls under ALL2008 protocol. Results: The mean number of toxicities per patient was similar between the protocols (2.5 [290/117] vs. 2.3 [547/234]). ALLTogether cohort had significantly greater weight gain, with over 50% experiencing a > 10% increase ( p < 0.01). Hyperglycemia (OR 5.17, 95% CI 1.93–13.82) and osteonecrosis (3.4% vs. 0%, p = 0.012) were more common, while liver dysfunction (0.59, 0.38–0.93) was less frequent in the ALLTogether protocol. The number of inpatient days was similar across protocols, except for the initial hospitalization, which was longer in ALLTogether (median 11 vs. 7 days, p < 0.01). Conclusions: The early introduction of asparaginase likely contributed to increased weight gain, hyperglycemia, and osteonecrosis. While overall toxicity burden remained similar between protocols, the shift in toxicity profile may explain the perception of increased early toxicity during treatment with the ALLTogether protocol. Trial Registration: ClinicalTrials.gov identifier: NCT03911128; EudraCT numbers: 2018‐001795‐38 and 2008‐003235‐20
- 20 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (2) , e32168
Open AccessEarly Toxicity in Childhood Acute Lymphoblastic Leukemia: A Comparison of NOPHO ALL2008 and ALLTogether Protocols in Sweden
Background: The European ALLTogether protocol for childhood acute lymphoblastic leukemia, initiated in Sweden 2019, introduced earlier asparaginase during induction, dexamethasone instead of prednisone for all patients, and omitted anthracyclines from low‐risk induction to reduce treatment‐related toxicity. Consolidation‐1 was based on the Induction 1B‐phase developed by the BFM‐group, replacing mercaptopurine, methotrexate, and asparaginase used in the previous NOPHO ALL2008 protocol, ALL2008. Following implementation, early treatment toxicity was considered unacceptably high, prompting a protocol amendment. We compared the prevalence of 14 predefined toxicities, the number of inpatient days, and weight changes during induction and consolidation‐1 between the two protocols. Methods: We conducted a population‐based cohort study in Sweden, reviewing patient records from 117 children treated under ALLTogether protocol and 234 matched controls under ALL2008 protocol. Results: The mean number of toxicities per patient was similar between the protocols (2.5 [290/117] vs. 2.3 [547/234]). ALLTogether cohort had significantly greater weight gain, with over 50% experiencing a > 10% increase ( p < 0.01). Hyperglycemia (OR 5.17, 95% CI 1.93–13.82) and osteonecrosis (3.4% vs. 0%, p = 0.012) were more common, while liver dysfunction (0.59, 0.38–0.93) was less frequent in the ALLTogether protocol. The number of inpatient days was similar across protocols, except for the initial hospitalization, which was longer in ALLTogether (median 11 vs. 7 days, p < 0.01). Conclusions: The early introduction of asparaginase likely contributed to increased weight gain, hyperglycemia, and osteonecrosis. While overall toxicity burden remained similar between protocols, the shift in toxicity profile may explain the perception of increased early toxicity during treatment with the ALLTogether protocol. Trial Registration: ClinicalTrials.gov identifier: NCT03911128; EudraCT numbers: 2018‐001795‐38 and 2008‐003235‐20
- Open Access
- 22 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32120
Infectious Complications During Early Treatment of Childhood Acute Lymphoblastic Leukemia—A Comparison Between the ALLTogether and NOPHO ALL‐2008 Protocols
Introduction: Infection remains the most common treatment‐related toxicity of childhood ALL, emphasizing the need to identify patients at risk and to tailor treatment strategies accordingly. Aims: The primary aim was to compare infectious toxicity during early treatment for childhood ALL following the ALLTogether and NOPHO ALL‐2008 (ALL‐2008) protocols, and second, to identify risk factors for infectious toxicity. Methods: A national retrospective matched cohort study was conducted, including 345 patients aged 1–17 years diagnosed with ALL and treated in Sweden according to the ALLTogether or ALL‐2008 protocols. Nonparametric tests were used to compare infectious outcomes between protocols, and regression modeling was used to identify risk factors of the infectious outcomes. Results: Treatment following ALL‐2008 showed higher infectious toxicity during induction, whereas treatment following ALLTogether showed increased infectious toxicity during consolidation 1. Overall, treatment according to ALL‐2008 was associated with a higher incidence of infections. Anthracycline use and young age (1–9 years) were associated with both higher infectious incidence and more severe infectious complications. Dexamethasone was associated with both lower incidence and lower severity of infectious complications as compared to prednisone. Conclusions: A notable shift in the timing of infectious toxicity was observed between the two treatment protocols. Risk factors for infectious toxicity during early treatment include anthracycline use and young age. Dexamethasone as an induction steroid was associated with lower infectious burden, although its effect is difficult to isolate from the simultaneous anthracycline effect. The findings suggest that treatment composition plays a central role in determining both the extent and timing of infectious complications.
- 22 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32120
Open AccessInfectious Complications During Early Treatment of Childhood Acute Lymphoblastic Leukemia—A Comparison Between the ALLTogether and NOPHO ALL‐2008 Protocols
Introduction: Infection remains the most common treatment‐related toxicity of childhood ALL, emphasizing the need to identify patients at risk and to tailor treatment strategies accordingly. Aims: The primary aim was to compare infectious toxicity during early treatment for childhood ALL following the ALLTogether and NOPHO ALL‐2008 (ALL‐2008) protocols, and second, to identify risk factors for infectious toxicity. Methods: A national retrospective matched cohort study was conducted, including 345 patients aged 1–17 years diagnosed with ALL and treated in Sweden according to the ALLTogether or ALL‐2008 protocols. Nonparametric tests were used to compare infectious outcomes between protocols, and regression modeling was used to identify risk factors of the infectious outcomes. Results: Treatment following ALL‐2008 showed higher infectious toxicity during induction, whereas treatment following ALLTogether showed increased infectious toxicity during consolidation 1. Overall, treatment according to ALL‐2008 was associated with a higher incidence of infections. Anthracycline use and young age (1–9 years) were associated with both higher infectious incidence and more severe infectious complications. Dexamethasone was associated with both lower incidence and lower severity of infectious complications as compared to prednisone. Conclusions: A notable shift in the timing of infectious toxicity was observed between the two treatment protocols. Risk factors for infectious toxicity during early treatment include anthracycline use and young age. Dexamethasone as an induction steroid was associated with lower infectious burden, although its effect is difficult to isolate from the simultaneous anthracycline effect. The findings suggest that treatment composition plays a central role in determining both the extent and timing of infectious complications.
- Open Access
- 27 August 2024
- Published by Wiley in Acta Paediatrica
- Vol. 113 (12) , 2676-2678
Haemostasis during early treatment of childhood acute lymphoblastic leukaemia with the ALLTogether protocol
- 27 August 2024
- Published by Wiley in Acta Paediatrica
- Vol. 113 (12) , 2676-2678
Open AccessHaemostasis during early treatment of childhood acute lymphoblastic leukaemia with the ALLTogether protocol